Ebixa® (Memantine Hydrochloride Tablets) is indicated for the treatment of moderate severe to severe dementia of the Alzheimer’s type. Since the commercial launch in China in 2006, its clinical efficacy and safety has been proved in more than 75 international and domestic clinical researches (about 23,000 patients) and unanimously recommended by international and local guidelines. Ebixa® with its excellent clinical efficacy and safety has won recognition from Chinese clinical physicians and patients. Ebixa® has so far been launched in more than 76 countries globally, and applied in clinical treatment for 15 years.